Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Road 5 Avenue 7, Banjara Hills, Hyderabad, India.
J Neurosci Methods. 2012 Aug 15;209(2):379-87. doi: 10.1016/j.jneumeth.2012.06.010. Epub 2012 Jun 23.
Measurement of unbound test compound concentrations at the biophase is routinely carried out in the drug discovery. Microdialysis is an established sampling technique for in vivo measurement of endogenous and exogenous compounds and it is commonly used for monitoring true concentrations. Endogenous compounds like neurotransmitters and neuropeptides in the brain are routinely evaluated as a proof of pharmacological activity of test compounds. Although, microdialysis offers several advantages over the conventional techniques for its use in brain pharmacokinetics, the absolute determination of extracellular concentrations of test compound depends on the predictable non-specific binding to the tubing and probe membrane. In the present investigation, we have demonstrated steps to predict non-specific binding and described approaches to reduce while working with compounds having different degree of adsorption properties. Non-specific binding to the tubing was measured in vitro for seven structurally diverse compounds and based on the binding characteristics, changes were adapted in study conditions. In vitro probe extraction efficiency was evaluated by gain and loss, which was further used as a second layer of measurement for non-specific binding. For selected compounds, in vivo probe extraction efficiencies were carried out and brain pharmacokinetics was evaluated in the prefrontal cortex of male Sprague-Dawley rats. Thus, the present approach demonstrates a systematic approach for evaluating and reducing the non-specific binding of test compounds to the microdialysis tubing and probe membranes. The stepwise approach described will strengthen the applicability of microdialysis in brain pharmacokinetics.
在药物发现中,常规进行生物相未结合测试化合物浓度的测量。微透析是一种用于测量内源性和外源性化合物的体内的既定采样技术,常用于监测真实浓度。内源性化合物,如大脑中的神经递质和神经肽,通常被评估为测试化合物的药理活性的证明。尽管微透析在脑药代动力学方面具有优于传统技术的几个优势,但测试化合物的细胞外浓度的绝对确定取决于与管和探针膜的可预测的非特异性结合。在本研究中,我们已经证明了预测非特异性结合的步骤,并描述了在处理具有不同吸附特性的化合物时减少非特异性结合的方法。对七种结构不同的化合物进行了体外管中非特异性结合的测量,并根据结合特性调整了研究条件。通过增益和损失评估了体外探针提取效率,并进一步将其用作非特异性结合的第二层测量。对于选定的化合物,进行了体内探针提取效率,并在雄性 Sprague-Dawley 大鼠的前额叶皮层中评估了脑药代动力学。因此,本方法展示了一种系统的方法,用于评估和减少测试化合物对微透析管和探针膜的非特异性结合。描述的逐步方法将增强微透析在脑药代动力学中的适用性。